Monoclonal antibodies: Pharmacological relevance

被引:4
作者
Kaur, Jasleen [1 ]
Badyal, O. K. [1 ]
Khosla, P. P. [1 ]
机构
[1] Christian Med Coll & Hosp, Dept Pharmacol, Ludhiana, Punjab, India
关键词
antibodies; biological response modifiers; cancer chemotherapy; immunosuppressant; immunotherapeutics;
D O I
10.4103/0253-7613.30755
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Monoclonal antibodies (MAbs), a new class of biological agents, are used these days in therapeutics and diagnosis. MAbs also labeled as 'magic bullets', are highly specific antibodies produced by a clone of single hybrid cells formed in the laboratory by fusion of B cell with the tumor cell. The hybridoma formed yields higher amount of MAbs. MAbs can be produced in vitro and in vivo. Animals are utilized to produce MAbs, but these antibodies are associated with immunogenic and ethical problems. Of late, recombinant DNA technology, genetic engineering,phage display and transgenic animals are used to produce humanized MAbs or pure human MAbs, which have fewer adverse effects. MAbs alone or conjugated with drugs, toxins, or radioactive atoms are used for treatment of cancer, autoimmune disorders, graft rejections, infectious diseases, asthma, and various cardiovascular disorders. New MAbs are being developed which are more specific and less toxic.
引用
收藏
页码:5 / 14
页数:10
相关论文
共 79 条
  • [11] Choroidal neovascularisation in pathological myopia: an update in management
    Chan, WM
    Ohji, M
    Lai, TYY
    Liu, DTL
    Tano, Y
    Lam, DSC
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 2005, 89 (11) : 1522 - 1528
  • [12] In vivo and in vitro production of monoclonal antibodies:: Current possibilities and future perspectives -: Introduction
    de Geus, B
    Hendriksen, CFM
    [J]. RESEARCH IN IMMUNOLOGY, 1998, 149 (06): : 533 - 534
  • [13] Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production
    DesaiMehta, A
    Lu, LJ
    RamseyGoldman, R
    Datta, SK
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (09) : 2063 - 2073
  • [14] Monoclonal antibodies and therapeutics
    Desgranges, C
    [J]. PATHOLOGIE BIOLOGIE, 2004, 52 (06): : 351 - 364
  • [15] Treatment of Waldenstrom's macroglobulinemia with thalidomide
    Dimopoulos, MA
    Zomas, A
    Viniou, NA
    Grigoraki, V
    Galani, E
    Matsouka, C
    Economou, O
    Anagnostopoulos, N
    Panayiotidis, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) : 3596 - 3601
  • [16] Dyer MJS, 1999, SEMIN ONCOL, V26, P52
  • [17] RANDOMIZED DOUBLE-BLIND COMPARISON OF CHIMERIC MONOCLONAL-ANTIBODY TO TUMOR-NECROSIS-FACTOR-ALPHA (CA2) VERSUS PLACEBO IN RHEUMATOID-ARTHRITIS
    ELLIOTT, MJ
    MAINI, RN
    FELDMANN, M
    KALDEN, JR
    ANTONI, C
    SMOLEN, JS
    LEEB, B
    BREEDVELD, FC
    MACFARLANE, JD
    BIJL, H
    WOODY, JN
    [J]. LANCET, 1994, 344 (8930) : 1105 - 1110
  • [18] A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer
    Elsaesser-Beile, Ursula
    Wolf, Philipp
    Gierschner, Dorothee
    Buehler, Patrick
    Schultze-Seemann, Wolfgang
    Wetterauer, Ulrich
    [J]. PROSTATE, 2006, 66 (13) : 1359 - 1370
  • [19] EVANS TL, 1988, BIOTECHNIQUES, V6, P762
  • [20] HYBRIDOMA ANTIBODY-PRODUCTION INVITRO IN TYPE-II SERUM-FREE MEDIUM USING NUTRIDOMA-SP SUPPLEMENTS - COMPARISONS WITH INVIVO METHODS
    FEDERSPIEL, G
    MCCULLOUGH, KC
    KIHM, U
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 1991, 145 (1-2) : 213 - 221